New Guardant Reveal offering provides oncologists with tissue-free solution to monitor treatment response and detect early disease progression with unprecedented speed and sensitivity Reveal is ...
Tissue-free Guardant Reveal test identifies disease progression up to 18 months earlier than standard clinical measures in patients with advanced cancer Longitudinal circulating tumor DNA (ctDNA) ...
Guardant Reveal fits easily into routine practice and provides timely, actionable insight—helping identify patients at high risk while sparing others unnecessary treatment and anxiety.” Today’s ...
Presentations highlight advancements in cancer recurrence detection with Guardant Reveal and real-time treatment response monitoring with Guardant360 Liquid Guardant Health, Inc. (Nasdaq: GH), a ...
Plenary session to highlight use of Guardant360 CDx test in detecting emerging ESR1 mutations during first line endocrine therapy in advanced breast cancer in Phase 3 SERENA-6 trial Oral session to ...
ctDNA testing post-surgery identifies high-risk stage 3 colon cancer patients more accurately than traditional staging methods. Detectable ctDNA correlates with a four- to six-fold increased risk of ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company and research collaborators at Mayo Clinic and the Alliance for Clinical Trials in Oncology today announced publication of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results